Dossier
Chinese biotech industry
Coverage of Chinese biotech industry in the Nexus archive.
- STAT+: A prominent VC explains why she’s against U.S. restrictions on investment in China’s drug industry
Legislators are pushing to expand the COINS Act to include biotechnology, allowing the U.S. government to restrict investments in the Chinese biotech industry. Venture capitalist Julie Grant opposes these restrictions, arguing they would hinder U.S. drug development and harm patients by disrupting decades-long industry interdependencies.
- Chinese drug reduces lung cancer death risk by 34% in trial
A Chinese lung cancer drug reduced the risk of death by 34% in a late-stage trial, extending survival by four months when combined with chemotherapy for squamous non-small-cell lung cancer. The results highlight China's growing pharmaceutical innovation, alongside global advancements like Eli Lilly's obesity drug and a pancreatic cancer treatment.